Literature DB >> 25960080

Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010.

J R Koethe1, C A Jenkins1, B Lau2, B E Shepherd1, M J Silverberg3, T T Brown2, A J Blashill4, A Anema5, A Willig6, S Stinnette7, S Napravnik7, J Gill8, H M Crane9, T R Sterling1.   

Abstract

OBJECTIVES: Adipose tissue affects several aspects of the cellular immune system, but prior epidemiological studies have differed on whether a higher body mass index (BMI) promotes CD4 T-cell recovery on antiretroviral therapy (ART). The objective of this analysis was to assess the relationship between BMI at ART initiation and early changes in CD4 T-cell count.
METHODS: We used the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) data set to analyse the relationship between pre-treatment BMI and 12-month CD4 T-cell recovery among adults who started ART between 1998 and 2010 and maintained HIV-1 RNA levels < 400 copies/mL for at least 6 months. Multivariable regression models were adjusted for age, race, sex, baseline CD4 count and HIV RNA level, year of ART initiation, ART regimen and clinical site.
RESULTS: A total of 8381 participants from 13 cohorts contributed data; 85% were male, 52% were nonwhite, 32% were overweight (BMI 25-29.9 kg/m(2) ) and 15% were obese (BMI > 30 kg/m(2) ). Pretreatment BMI was associated with 12-month CD4 T-cell change (P < 0.001), but the relationship was nonlinear (P < 0.001). Compared with a reference of 22 kg/m(2) , a BMI of 30 kg/m(2) was associated with a 36 cells/μL [95% confidence interval (CI) 14, 59 cells/μL] greater CD4 T-cell count recovery among women and a 19 cells/μL (95% CI 9, 30 cells/μL) greater recovery among men at 12 months. At a BMI > 30 kg/m(2) , the observed benefit was attenuated among men to a greater degree than among women, although this difference was not statistically significant.
CONCLUSIONS: A BMI of approximately 30 kg/m(2) at ART initiation was associated with greater CD4 T-cell recovery at 12 months compared with higher or lower BMI values, suggesting that body composition may affect peripheral CD4 T-cell recovery.
© 2015 British HIV Association.

Entities:  

Keywords:  HIV; antiretroviral therapy; immune reconsitition; nutrition; obesity

Mesh:

Substances:

Year:  2015        PMID: 25960080      PMCID: PMC4558259          DOI: 10.1111/hiv.12259

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  17 in total

1.  Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Authors:  Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore
Journal:  Int J Epidemiol       Date:  2007-01-08       Impact factor: 7.196

2.  CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

Authors:  Richard D Moore; Jeanne C Keruly
Journal:  Clin Infect Dis       Date:  2006-12-20       Impact factor: 9.079

3.  A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia.

Authors:  Valerianna Amorosa; Marie Synnestvedt; Robert Gross; Harvey Friedman; Rob Roy MacGregor; Debie Gudonis; Ian Frank; Pablo Tebas
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-15       Impact factor: 3.731

4.  Obesity among HIV-infected persons: impact of weight on CD4 cell count.

Authors:  Nancy F Crum-Cianflone; Mollie Roediger; Lynn E Eberly; Kurt Vyas; Mike L Landrum; Anuradha Ganesan; Amy C Weintrob; Robert Vincent Barthel; Brian K Agan
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

5.  Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy.

Authors:  Elif Arioglu Oral; Edward D Javor; Li Ding; Gulbu Uzel; Elaine K Cochran; Janice Ryan Young; Alex M DePaoli; Steven M Holland; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2005-11-29       Impact factor: 5.958

6.  Obesity and immune cell counts in women.

Authors:  Julie Womack; Phyllis C Tien; Joseph Feldman; Ja Hyun Shin; Kristopher Fennie; Kathryn Anastos; Mardge H Cohen; Melanie C Bacon; Howard Minkoff
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

7.  Increasing rates of obesity among HIV-infected persons during the HIV epidemic.

Authors:  Nancy Crum-Cianflone; Mollie Poehlman Roediger; Lynn Eberly; Maryam Headd; Vincent Marconi; Anuradha Ganesan; Amy Weintrob; R Vincent Barthel; Susan Fraser; Brian K Agan
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

8.  HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.

Authors:  Charlotte Lewden; Genevieve Chene; Philippe Morlat; Francois Raffi; Michel Dupon; Pierre Dellamonica; Jean-Luc Pellegrin; Christine Katlama; Francois Dabis; Catherine Leport
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

9.  Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases.

Authors:  Jason V Baker; Grace Peng; Joshua Rapkin; David Krason; Cavan Reilly; Winston P Cavert; Donald I Abrams; Rodger D MacArthur; Keith Henry; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-15       Impact factor: 3.731

10.  Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.

Authors:  I Sadaf Farooqi; Giuseppe Matarese; Graham M Lord; Julia M Keogh; Elizabeth Lawrence; Chizo Agwu; Veronica Sanna; Susan A Jebb; Francesco Perna; Silvia Fontana; Robert I Lechler; Alex M DePaoli; Stephen O'Rahilly
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

View more
  20 in total

1.  High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC.

Authors:  M E Levy; A E Greenberg; R Hart; L Powers Happ; C Hadigan; A Castel
Journal:  HIV Med       Date:  2017-05-15       Impact factor: 3.180

2.  Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.

Authors:  Vincent Madelain; Minh P Le; Karen Champenois; Charlotte Charpentier; Roland Landman; Veronique Joly; Patrick Yeni; Diane Descamps; Yazdan Yazdanpanah; Gilles Peytavin
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

3.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

4.  HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer.

Authors:  Barbara S Taylor; Kaku So-Armah; Janet P Tate; Vincent C Marconi; John R Koethe; Roger J Bedimo; Adeel A Butt; Cynthia L Gibert; Matthew B Goetz; Maria C Rodriguez-Barradas; Julie A Womack; Mariana Gerschenson; Vincent Lo Re; David Rimland; Michael T Yin; David Leaf; Russell P Tracy; Amy C Justice; Matthew S Freiberg
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

5.  Effect of BMI and fat mass on HIV disease progression in HIV-infected, antiretroviral treatment-naïve adults in Botswana.

Authors:  S S Martinez; A Campa; H Bussmann; S Moyo; J Makhema; F G Huffman; O D Williams; M Essex; R Marlink; M K Baum
Journal:  Br J Nutr       Date:  2016-04-18       Impact factor: 3.718

6.  Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Authors:  Damalie Nakanjako; Agnes N Kiragga; Beverly S Musick; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Lameck Diero; Patrick Oyaro; Emanuel Lugina; John C Ssali; Andrew Kambugu; Philippa Easterbrook
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

7.  Leptin expression in HIV-infected patients during antiretroviral therapy.

Authors:  Cătălin Tiliscan; Victoria Aramă; Raluca Mihăilescu; Daniela Ioana Munteanu; Adrian Streinu-Cercel; Daniela Adriana Ion; Mihaela Andreea Rădulescu; Cristina Popescu; Alina Elena Lobodan; Anca Ruxandra Negru; Ştefan Sorin Aramă
Journal:  Germs       Date:  2015-09-01

8.  Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment.

Authors:  John R Koethe; Cathy A Jenkins; Bryan Lau; Bryan E Shepherd; William Wester; Peter F Rebeiro; Michael J Silverberg; Jennifer E Thorne; John Gill; Angel M Mayor; Amanda Willig; Ronald Bosch; Michael A Horberg; Amy C Justice; Timothy R Sterling; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2016-10-01       Impact factor: 3.731

9.  Brief Report: Adipogenic Expression of Brown Fat Genes in HIV and HIV-Related Parameters.

Authors:  Suman Srinivasa; Martin Torriani; Kathleen V Fitch; Patrick Maehler; Sanjna Iyengar; Meghan Feldpausch; Aaron M Cypess; Steven K Grinspoon
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-15       Impact factor: 3.731

10.  Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.

Authors:  Julie B Dumond; Camden P Bay; Julie A E Nelson; Angel Davalos; Andrew Edmonds; Kristina De Paris; Craig Sykes; Kathryn Anastos; Roopali Sharma; Seble Kassaye; Bani Tamraz; Audrey L French; Stephen Gange; Ighovwerha Ofotokun; Margaret A Fischl; David E Vance; Adaora A Adimora
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.